Debbie's Place

A Patient's Point of View

AM-1710– synthetic, CB2 agonist

 AM-1710synthetic, CB2 agonist

 

Pharmacological characterization of AM1710, a putative cannabinoid CB(2) agonist from the cannabilactone class: Antinociception without central nervous system side-effects. (abst – 2011)  http://www.unboundmedicine.com/medline/ebm/record/21382397/abstract/Pharmacological_characterizati

 

on_of_AM1710_a_putative_cannabinoid_CB_2 n_without_central_nervous_system_side_effects_


agonist_from_the_cannabilactone_class:_Antinociceptio

 

 

The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB2 receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy                                                   (full – 2012)  http://www.molecularpain.com/content/8/1/71

 

Intrathecal cannabilactone CB(2)R agonist, AM1710, controls pathological pain and restores basal cytokine levels.                                  (abst – 2012)  http://www.ncbi.nlm.nih.gov/pubmed/22425445

 

The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB2 receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy.                                                    (abst – 2012)  http://www.ncbi.nlm.nih.gov/pubmed/22998838

 

 

 

 

 

Share a link for

1 Comment

  1. My brother suggested I might like this web site. He was totally right. This post truly made my day. You can not imagine just how much time I had spent for this info! Thanks!

Leave a Reply

Your email address will not be published.

*

© 2019 Debbie's Place

Powered by

www.420.ag